Mazor Robotics (MZOR) Earns Daily Coverage Optimism Score of 0.17
Headlines about Mazor Robotics (NASDAQ:MZOR) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mazor Robotics earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 45.7383212297221 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Several equities research analysts recently issued reports on MZOR shares. Ladenburg Thalmann Financial Services set a $54.00 target price on shares of Mazor Robotics and gave the stock a “buy” rating in a report on Wednesday, August 30th. Needham & Company LLC reissued a “hold” rating on shares of Mazor Robotics in a report on Wednesday, August 30th. Zacks Investment Research lowered shares of Mazor Robotics from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. TheStreet raised shares of Mazor Robotics from a “d” rating to a “c-” rating in a report on Wednesday, November 8th. Finally, Barclays lowered shares of Mazor Robotics from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $55.00 to $34.00 in a report on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $39.83.
Shares of Mazor Robotics (MZOR) opened at $57.83 on Friday. Mazor Robotics has a fifty-two week low of $20.50 and a fifty-two week high of $65.97.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.